A study about combination cancer treatments for people with acute myeloid leukemia or multiple myeloma
The TTI-622-01 (C4971001) study is testing an investigational study medicine for people with acute myeloid leukemia or multiple myeloma. The study medicine works by blocking signals in your immune system, allowing it to attack and kill the cancer cells.
Who may participate
Joining a clinical trial is an important and personal decision. Thank you for considering the TTI-622-01 (C4971001) study.
This study may be an option for men and women aged 18 and older who have acute myeloid leukemia or multiple myeloma.
If this study may be a fit for you, you’ll review the details with the study team and get to ask any questions you have. If you choose to participate, you will sign an informed consent document and continue to a screening appointment. This is to confirm you meet the eligibility criteria and are able to participate.
Acute myeloid leukemia or multiple myeloma
18 years and older
Male or Female
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
Study participants can expect to be in the study for up to 42 months. During this time, participants may continue to receive the study treatments until they no longer benefit from them.
The total time in the study depends upon how well a study participant tolerates the study medicine and how their cancer responds to the treatment(s).
Length of study treatment
Up to 42 months
Number of study visits
At least weekly
Frequently asked questions
Acute myeloid leukemia (AML) is a blood cancer that starts in the bone marrow and spreads to the blood. In AML, the body overproduces immature blood cells that, unable to function properly, end up crowding out healthy blood cells.
Multiple myeloma is a type of blood cancer that forms in bone marrow. Healthy bone marrow produces plasma cells, which make antibodies to fight infection. But in multiple myeloma, plasma cells become cancerous. These cancer cells can crowd out normal blood cells, forming tumors and leaving a person vulnerable to infection.
The study medicine works by helping your immune system to target and kill cancer cells.